Indus Health Network (IHN) signed a Memorandum of Understanding on July 4, 2018, with the Government of Baluchistan. The purpose is to eradicate TB from the province. IHN’s CEO, Professor Dr. Abdul Bari Khan and Interim Health Minister, Baluchistan, Faiz Kakar signed the MoU. The signing ceremony took place in Quetta.
Dr. Nida Ilyas Shamsi, Assistant Professor, Family Medicine, Indus Health Network (IHN) participated in the 14th annual International Conference for Clinical Ethics Consultation (ICCEC). She shared her experience of establishing a Clinical Ethics Committee at the Indus Hospital (TIH), Karachi in the context of its unique placement in Pakistan’s healthcare system.
Major Uzair Khan, Assistant Manager, Safety and Security Department, Indus Health Network has recently been appointed as the Chair for Europe and Middle East Region for International Association for Healthcare Security & Safety (IAHSS). IAHSS is a leading international organization which is solely devoted for healthcare security, safety and emergency management. It has 11 regions worldwide.
The Indus Hospital (TIH), Karachi conducted an awareness session on ‘Palliative and End-of-Life Care – The Islamic Perspective’, on Thursday, May 31, 2018. Renowned religious scholar, Mufti Mohammad Taqi Usmani was the keynote speaker. Palliative care is not just for the end of life, patient may receive palliative care earlier in illness while they are still receiving other therapies to treat the physical, psychological, spiritual and social needs of both patient and the family. Dignity of the patient is imperative.
The Indus Hospital has conducted a community engagement program on April 21, 2018, for its Cochlear Implant (CI) patients and their families. The patients remain in contact with the CI team for at least three years, therefore, it’s important to have cordial relationship with them. The purpose of the event was to introduce the team and program’s objectives to the audience.
Since April 2018, Nucleic Acid Testing (NAT) using Polymerase Chain Reaction (PCR) technology is being used for identifying Hepatitis B and Hepatitis C viruses on every single donor in addition to CLIA which was already being performed. Thus fulfilling FDA (USA) requirement for donor screening.